Repare Therapeutics Inc (RPTX) Stock Price, Quote & News

Company Profile

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 412 7018

Website: www.reparerx.com

Address:

7171 Frederick-Banting, Building 2, Suite 270 St-Laurent, Montreal, Canada

SecondChances Oct. 22 at 10:44 PM

$RPTX 16% ORR in heavily pretreated patients. Not bad.

0 · Reply

Doozio Oct. 21 at 6:34 PM

$RPTX scrabble bag it. 🐒🍌🧠⏰♾️

0 · Reply

RobertMcmillan729 Oct. 20 at 4:20 PM

$RPTX discovering therapies; AITX discovering efficiencies — from sales rollups to profitability, progress keeps stacking.

0 · Reply

hbkstockislife Oct. 16 at 9:35 PM

$RPTX people still in this scam ..good .

0 · Reply

RDequities Oct. 16 at 2:01 PM

$RPTX one of the most worthless stock of all time ..award goes to this one (one of many scams)

1 · Reply

Wakaas93 Oct. 15 at 7:52 AM

$RPTX Started buying Data 25th October

0 · Reply

Wakaas93 Oct. 14 at 7:06 PM

$RPTX https://x.com/maximus_holla/status/1978159735800058161?s=46

0 · Reply

Wakaas93 Oct. 14 at 7:05 PM

$RPTX When is data?

0 · Reply

Red2Profit Oct. 13 at 8:48 PM

0 · Reply

Mr__Man Sep. 5 at 2:52 PM

$RPTX

0 · Reply

Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Aug 8, 2025, 7:00 AM EDT - 2 months ago

Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Jul 15, 2025, 4:05 PM EDT - 3 months ago

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

May 13, 2025, 4:05 PM EDT - 5 months ago

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results

May 1, 2025, 7:00 AM EDT - 6 months ago

Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

May 1, 2025, 7:00 AM EDT - 6 months ago

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

Apr 25, 2025, 1:00 PM EDT - 6 months ago

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

Mar 31, 2025, 4:39 PM EDT - 7 months ago

Repare Therapeutics Announces Leadership Transitions

Mar 7, 2025, 4:05 PM EST - 8 months ago

Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 3, 2025, 7:05 AM EST - 8 months ago

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Jan 9, 2025, 4:05 PM EST - 10 months ago

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

Dec 13, 2024, 12:09 PM EST - 11 months ago

Why Is Repare Therapeutics Stock Trading Lower On Friday?

Dec 12, 2024, 4:20 PM EST - 11 months ago

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Dec 10, 2024, 4:05 PM EST - 11 months ago

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

Nov 12, 2024, 7:05 AM EST - 1 year ago

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib

Nov 7, 2024, 7:05 AM EST - 1 year ago

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results

Oct 23, 2024, 6:05 AM EDT - 1 year ago

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial

Oct 14, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor

Sep 30, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting

Sep 23, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024

Aug 30, 2024, 6:13 PM EDT - 1 year ago

Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data

Aug 28, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio

Aug 27, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics to Participate in Two Upcoming Investor Conferences

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results

Jun 26, 2024, 10:30 AM EDT - 1 year ago

Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI

Jun 12, 2024, 7:00 AM EDT - 1 year ago

Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib

Jun 10, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial

Jun 4, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer

Jun 3, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 29, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024

May 7, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results

Apr 30, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition

Apr 30, 2024, 7:05 AM EDT - 1 year ago

Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition

Apr 26, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Appoints Steven H. Stein, M.D.

Mar 21, 2024, 10:00 AM EDT - 1 year ago

Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Feb 28, 2024, 7:05 AM EST - 1 year ago

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 15, 2024, 7:05 AM EST - 1 year ago

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664

Feb 12, 2024, 4:05 PM EST - 1 year ago

Repare Therapeutics to Regain Global Rights to Camonsertib

Jan 25, 2024, 7:00 AM EST - 1 year ago

Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment

Jan 8, 2024, 7:00 AM EST - 1 year ago

Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones

Jan 4, 2024, 4:10 PM EST - 1 year ago

Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer

Jan 4, 2024, 4:05 PM EST - 1 year ago

Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer

Dec 29, 2023, 4:05 PM EST - 1 year ago

Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans

Nov 15, 2023, 7:00 AM EST - 2 years ago

Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor

SecondChances Oct. 22 at 10:44 PM

$RPTX 16% ORR in heavily pretreated patients. Not bad.

0 · Reply

Doozio Oct. 21 at 6:34 PM

$RPTX scrabble bag it. 🐒🍌🧠⏰♾️

0 · Reply

RobertMcmillan729 Oct. 20 at 4:20 PM

$RPTX discovering therapies; AITX discovering efficiencies — from sales rollups to profitability, progress keeps stacking.

0 · Reply

hbkstockislife Oct. 16 at 9:35 PM

$RPTX people still in this scam ..good .

0 · Reply

RDequities Oct. 16 at 2:01 PM

$RPTX one of the most worthless stock of all time ..award goes to this one (one of many scams)

1 · Reply

Wakaas93 Oct. 15 at 7:52 AM

$RPTX Started buying Data 25th October

0 · Reply

Wakaas93 Oct. 14 at 7:06 PM

$RPTX https://x.com/maximus_holla/status/1978159735800058161?s=46

0 · Reply

Wakaas93 Oct. 14 at 7:05 PM

$RPTX When is data?

0 · Reply

Red2Profit Oct. 13 at 8:48 PM

0 · Reply

Mr__Man Sep. 5 at 2:52 PM

$RPTX

0 · Reply

NVDAMillionaire Sep. 4 at 12:25 PM

$RPTX Great piece that accurately captures RPTX's current position. So if you want to refresh your understanding of RPTX or learn about RPTX for the first time, this is essential reading. https://beyondspx.com/quote/RPTX/repare-therapeutics-unlocking-value-with-a-sharpened-precision-oncology-pipeline-rptx#analysis

0 · Reply

LabPsycho Sep. 3 at 2:13 PM

$RPTX @Mnof Now that is an outstanding post! Bonus points for original thinking and supportive documentation.

1 · Reply

SecondChances Sep. 3 at 5:14 AM

$RPTX better things to come. https://pmc.ncbi.nlm.nih.gov/articles/PMC12234790/

1 · Reply

Sixth_Sense Sep. 2 at 8:23 PM

$RPTX about to get cooking here 👀

1 · Reply

MUBSN Sep. 2 at 7:44 PM

$RPTX just bought only 3136 RPTX at 1.66

0 · Reply

Mnof Sep. 1 at 1:27 PM

$RPTX Not publicized. Primary completion Phase 2 end this month. Topline thereafter; Memorial Sloan Kettering sponsored Ph1/2 trial using external beam radio therapy (EBRT) with camonsertib on cancer metastases in patients having ATM mutations https://www.clinicaltrials.gov/study/NCT05566574?term=NCT05566574&rank=1 Ph1 results earlier this year were v. good https://www.reparerx.com/wp-content/uploads/2024/09/RP3500-ASTRO-Poster.pdf and caused an AH blip in price. Therapy is 5 shots of camonsertib prior to ERBT. Inhibition of ATR (camonsertib) along with RT induces synthetic lethality in tumors with loss of function (LoF) ATM mutations. Efficacy here has blockbuster potential, considering total addressable market (TAM). For instance, 5.4% of random tumor patients (n=20,107) were found to harbour somatic/germline ATM mutations https://pmc.ncbi.nlm.nih.gov/articles/PMC7936050/ LoF ATM mutation tumor types on p53 wt background responded favorably to RT over variants of unknown significance. 1.35% of n=20.1k will be LoF ATM and p53wt. Dr. Lee author here also the PI on trial. Camonsertib the new radiosensitizer?

0 · Reply

JunkPost Aug. 27 at 8:04 PM

$RPTX It is time to move up

0 · Reply

paddyTC Aug. 27 at 6:27 PM

$RPTX POLAR details are impressive , potentially a blockbuster

1 · Reply

belugatrade Aug. 27 at 5:19 PM

$RPTX wants to pop

0 · Reply

Mnof Aug. 8 at 4:21 PM

$RPTX Q2 loss reduced to -$0.39 EPS, estimates were -$0.56, earnings surprise of +30.36%. Burn reduced to 14.5m/Q with $109.5m cash on hand. Cash runway through 2027. However, Phase 1 POLAR top-line shifted from 3Q to 4Q this year, phase 1 LIONS top-line still on track for Q4 this year. https://ir.reparerx.com/static-files/b976f77c-5960-48e2-8d02-31105c333d98

0 · Reply

d_risk Aug. 8 at 2:50 PM

$RPTX - Repare Therapeutics Inc. Common Shares - 10Q - Updated Risk Factors RPTX flags major new risks from evolving healthcare laws like ACA, IRA, and OBBBA impacting drug pricing, approvals, and reimbursement, plus fresh concerns that tax law changes could materially hit shareholder returns. #HealthcareLaws #PharmaceuticalIndustry #TaxLawImpact #RegulatoryRisk #DrugPricing 🟢 Added 🟠 Removed https://d-risk.ai/RPTX/10-Q/2025-08-08

0 · Reply

stockanalysis_ Aug. 8 at 1:35 PM

Earnings after the close today: $CORZ $HRTX $WHG $LFT $RPTX View the list here: https://stockanalysis.com/stocks/earnings-calendar/?ref=saveontrading

0 · Reply

Market Cap	84.20M
Revenue (ttm)	53.48M
Net Income (ttm)	-84.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-158.36%
Debt to Equity Ratio	0.00

Volume	149,270
Avg Vol	128,296
Day's Range	N/A - N/A
Shares Out	42.96M
Stochastic %K	96%
Beta	1.08
Analysts	Sell
Price Target	$5.00